Seelos Stock Today

SEEL
 Stock
  

USD 0.69  0.04  6.15%   

Market Performance
0 of 100
Odds Of Distress
Over 64
Seelos Therapeutics is selling for 0.69 as of the 29th of June 2022. This is a 6.15 percent up since the beginning of the trading day. The stock's lowest day price was 0.61. Seelos Therapeutics has more than 64 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Seelos Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of May 2022 and ending today, the 29th of June 2022. Click here to learn more.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York. The company has 105.5 M outstanding shares of which 8.85 M shares are at this time shorted by private and institutional investors with about 7.31 trading days to cover. More on Seelos Therapeutics

Moving together with Seelos Therapeutics

0.76MRNAModerna Potential GrowthPairCorr
0.81ALNAAllena Pharmaceuticals TrendingPairCorr
Seelos Therapeutics cannot be verified against its exchange. Apparently, Seelos Therapeutics is not available for investing at the moment. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid please let us know and we will check it as soon as possible.
Refresh

Seelos Therapeutics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Seelos Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Seelos Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Seelos Therapeutics is not yet fully synchronised with the market data
Seelos Therapeutics has some characteristics of a very speculative penny stock
Seelos Therapeutics has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (66.05 M) with loss before overhead, payroll, taxes, and interest of (46.65 M).
Seelos Therapeutics currently holds about 78.73 M in cash with (48.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.75.
Seelos Therapeutics has a poor financial position based on the latest SEC disclosures
ChairmanRaj Mehra
Average Analyst Recommendation
Analysts covering Seelos Therapeutics report their recommendations after researching Seelos Therapeutics' financial statements, talking to executives and customers, or listening in on Seelos Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Seelos Therapeutics. The Seelos consensus assessment is calculated by taking the average forecast from all of the analysts covering Seelos Therapeutics.
Strong Buy6 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Seelos Therapeutics based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Seelos Therapeutics financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 4 - PoorDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares98.1 M90.9 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted98.1 M90.9 M
Significantly Up
Increasing
Slightly volatile
Total Assets90.1 M83.5 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities28.2 M26.2 M
Significantly Up
Increasing
Slightly volatile
Current Assets90.1 M83.5 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities9.1 M8.3 M
Significantly Up
Decreasing
Very volatile
Return on Average Assets(141)(131)
Significantly Down
Decreasing
Stable
Gross Margin34.0829.23
Fairly Up
Decreasing
Very volatile
Asset Turnover0.04660.0454
Fairly Up
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Seelos Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Not RatedUndervalued
Seelos Therapeutics (SEEL) is traded on NASDAQ Exchange in USA and employs 15 people. The company currently falls under 'Micro-Cap' category with current market capitalization of 74.69 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Seelos Therapeutics's market, we take the total number of its shares issued and multiply it by Seelos Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Seelos Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 105.5 M outstanding shares of which 8.85 M shares are at this time shorted by private and institutional investors with about 7.31 trading days to cover. Seelos Therapeutics currently holds about 78.73 M in cash with (48.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.75.
Check Seelos Therapeutics Probability Of Bankruptcy

Seelos Therapeutics Historical Income Statement

Seelos Therapeutics Income Statement is one of the three primary financial statements used for reporting Seelos's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Seelos Therapeutics revenue and expense. Seelos Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Seelos Therapeutics Revenues is relatively stable at the moment as compared to the past year. The company's current value of Revenues is estimated at 442,598. Weighted Average Shares is expected to hike to about 98.1 M this year, although the value of Net Income will most likely fall to (67.8 M). View More Fundamentals

Seelos Stock Against Markets

Picking the right benchmark for Seelos Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Seelos Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Seelos Therapeutics is critical whether you are bullish or bearish towards Seelos Therapeutics at a given time.
Seelos Therapeutics cannot be verified against its exchange. Apparently, Seelos Therapeutics is not available for investing at the moment. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid please let us know and we will check it as soon as possible.
Refresh

Try Other Stock Suggestions

Be your own money manager

Our tools can tell you how much better you can do entering a position in Seelos Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Suggestion Now

   

Portfolio Suggestion

Get suggestions outside of your existing asset allocation including your own model portfolios
All  Next Launch Module

Seelos Therapeutics Corporate Directors

Seelos Therapeutics corporate directors refer to members of a Seelos Therapeutics board of directors. The board of directors generally takes responsibility for the Seelos Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Seelos Therapeutics' board members must vote for the resolution. The Seelos Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.

Investing Seelos Therapeutics

You need to understand the risk of investing before taking a position in Seelos Therapeutics. The danger of trading Seelos Therapeutics is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Seelos Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Seelos Therapeutics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Seelos Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additionally, take a look at World Market Map. Note that the Seelos Therapeutics information on this page should be used as a complementary analysis to other Seelos Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Complementary Tools for Seelos Stock analysis

When running Seelos Therapeutics price analysis, check to measure Seelos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seelos Therapeutics is operating at the current time. Most of Seelos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seelos Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Seelos Therapeutics' price. Additionally, you may evaluate how the addition of Seelos Therapeutics to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Is Seelos Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seelos Therapeutics. If investors know Seelos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seelos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Seelos Therapeutics is measured differently than its book value, which is the value of Seelos that is recorded on the company's balance sheet. Investors also form their own opinion of Seelos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seelos Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seelos Therapeutics' market value can be influenced by many factors that don't directly affect Seelos Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seelos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Seelos Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seelos Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.